Novelion CEO quits Novo Nordisk board due to NASH conflict

(Reuters) - Danish drugmaker Novo Nordisk said on Tuesday the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to "a potential conflict of interest".